OS Therapies Incorporated (OSTX) Stock Ticker
Market factors today
Unlock the full OSTX picture
About OS Therapies Incorporated
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Grasonville, Maryland.
OSTX stock facts
| Ticker symbol | OSTX |
| Exchange | New York Stock Exchange Arca |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $75.6M |
| CEO | Paul A. Romness |
| Employees | 5 |
| Headquarters | Grasonville, MD, US |
| IPO date | 2024-08-01 |
| Website | ostherapies.com |
What you can see for OSTX on Tickr
Live OSTX price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the OSTX report.
Rankings
FAQ
What is the ticker symbol for OS Therapies Incorporated?
The ticker symbol for OS Therapies Incorporated is OSTX, listed on the New York Stock Exchange Arca.
What is OSTX?
OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide…